AstraZeneca And Astellas Enter Agreement for Co-Promotion of Symbicort Turbuhaler in Japan
- Details
- Category: AstraZeneca
AstraZeneca and Astellas Pharma Inc. announced an agreement for the co-promotion of AstraZeneca's Symbicort Turbuhaler (budesonide/ formoterol, a dry powder inhaler), for the treatment of bronchial asthma in Japan. Under the agreement, AstraZeneca and Astellas will co-promote Symbicort Turbuhaler and Astellas will be responsible for distribution of the product.
GlaxoSmithKline update: Government orders for pandemic (H1N1) 2009 vaccine
- Details
- Category: GlaxoSmithKline
On the 22nd July, the company confirmed that it had contracts in place to supply 195 million doses of its pandemic (H1N1) 2009 adjuvanted influenza vaccine and had a variety of agreements in place with the US Government to supply pandemic products worth $250 million. Since that date, nine government contracts have been signed for a further 96 million doses of the vaccine.
Avastin approved in US for the most common type of kidney cancer
- Details
- Category: Roche
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) plus interferon alpha for people with metastatic renal cell carcinoma, the most common type of kidney cancer.
Nycomed to acquire local portfolio from Sanofi-Aventis and Zentiva
- Details
- Category: Nycomed
Nycomed agreed with Sanofi-Aventis and Zentiva to purchase 20 branded generic products in several Central and Eastern European countries. The agreement will notably strengthen Nycomed's market position in particular in the Czech Republic and Slovakia.
FDA Approves ONGLYZA for the Treatment of Type 2 Diabetes in the US
- Details
- Category: AstraZeneca
AstraZeneca and Bristol-Myers Squibb today announced that the US Food and Drug Administration (FDA) has approved ONGLYZA (saxagliptin) for the treatment of type 2 diabetes mellitus in adults.
AstraZeneca PLC Second Quarter & Half Year Results 2009
- Details
- Category: AstraZeneca
Sales in the second quarter increased by 9 percent at CER, but were flat on an actual basis as a result of the negative impact of exchange rate movements. Sales benefited from strong growth of the Toprol-XL franchise in the US as a result of the market withdrawal by two generic competitors; adjusting for this, global sales increased by 6 percent.
Good first six months in 2009 for Boehringer Ingelheim
- Details
- Category: Boehringer Ingelheim
The pharmaceutical company Boehringer Ingelheim again posted gratifying growth in local currency (+8.3 percent) over the previous year in the first six months of 2009. Consolidated in euro, this reflected growth of + 15.7 percent thanks to the positive exchange rates, with net sales of EUR 6,388 million compared with EUR 5,522 million in the first six months of the previous year.
More Pharma News ...
- Pfizer in Partnership with Shanghai Institutes for Biological Sciences for Drug Discovery Activities
- Abbott to Acquire Nutrition Businesses, Expanding Presence in India
- Amgen to collaborate with GSK to commercialize denosumab in Europe for postmenopausal osteoporosis
- Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
- Q2/2009: Merck Revenues Remain Steady at € 1.9 Billion
- The US Food and Drug Administration (FDA) has approved Tekturna HCT®
- Genzyme Delivers Solid Second-Quarter Financial Results